Furthermore, individuals with MASLD exhibited compromised insulin-induced inhibition of VLDL kinetics, leading to increased VLDL concentrations as well as apoB100 in those with elevated IHTG content, in contrast to those with low IHTG levels [76,198]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.